Known hypersensitivity to egg, soybean proteins, peanut proteins, corn or corn products, or to any of the active substances or excipients
Severe hyperlipidemia or severe disorders of lipid metabolism characterized by hypertriglyceridemia (serum triglyceride concentration >1,000 g/dL).
Inborn errors of amino acid metabolism
Cardiopulmonary instability (including pulmonary edema, cardiac insufficiency, myocardial infarction, acidosis and hemodynamic instability requiring significant vasopressor support)
Hemophagocytic syndrome.
PN in the last 7 days prior to study enrollment.
Need for chronic PN before study start
Liver enzymes (either AST, ALT, GGPT), or direct bilirubin exceeding 2 x upper limit of normal range
Pathologically altered level of any serum electrolyte (sodium, potassium, magnesium, calcium, chloride, phosphate) unless corrected prior to the start of study treatment
Pathologically altered blood pH, or oxygen saturation, or carbon dioxide unless corrected prior to the start of study treatment
Pregnancy or lactation
Participation in another clinical study

NCT03481894_exc_T1
Condition
hypersensitivity
NCT03481894_exc_T2
Drug
egg
NCT03481894_exc_T3
Drug
soybean proteins
NCT03481894_exc_T4
Drug
peanut proteins
NCT03481894_exc_T5
Drug
corn
NCT03481894_exc_T6
Drug
corn products
NCT03481894_exc_T7
Drug
active substances
NCT03481894_exc_T8
Drug
excipients
NCT03481894_exc_T9
Scope
egg, soybean proteins, peanut proteins, corn or corn products, or to any of the active substances or excipients
NCT03481894_exc_T10
Condition
hyperlipidemia
NCT03481894_exc_T11
Qualifier
Severe
NCT03481894_exc_T12
Qualifier
severe
NCT03481894_exc_T13
Condition
disorders of lipid metabolism
NCT03481894_exc_T14
Condition
hypertriglyceridemia
NCT03481894_exc_T15
Measurement
serum triglyceride concentration
NCT03481894_exc_T16
Value
>1,000 g/dL
NCT03481894_exc_T17
Condition
Inborn errors of amino acid metabolism
NCT03481894_exc_T18
Condition
Cardiopulmonary instability
NCT03481894_exc_T19
Condition
pulmonary edema
NCT03481894_exc_T20
Condition
cardiac insufficiency
NCT03481894_exc_T21
Condition
myocardial infarction
NCT03481894_exc_T22
Condition
acidosis
NCT03481894_exc_T23
Condition
hemodynamic instability
NCT03481894_exc_T24
Qualifier
vasopressor support
NCT03481894_exc_T25
Qualifier
significant
NCT03481894_exc_T26
Drug
vasopressor
NCT03481894_exc_T27
Scope
pulmonary edema, cardiac insufficiency, myocardial infarction, acidosis and hemodynamic instability requiring significant vasopressor support
NCT03481894_exc_T28
Condition
Hemophagocytic syndrome
NCT03481894_exc_T29
Procedure
PN
NCT03481894_exc_T30
Temporal
in the last 7 days prior to study enrollment
NCT03481894_exc_T31
Reference_point
study enrollment
NCT03481894_exc_T32
Procedure
chronic PN
NCT03481894_exc_T33
Temporal
before study start
NCT03481894_exc_T34
Reference_point
study start
NCT03481894_exc_T35
Measurement
Liver enzymes
NCT03481894_exc_T36
Measurement
AST
NCT03481894_exc_T37
Measurement
ALT
NCT03481894_exc_T38
Measurement
GGPT
NCT03481894_exc_T39
Measurement
direct bilirubin
NCT03481894_exc_T40
Value
exceeding 2 x upper limit of normal range
NCT03481894_exc_T41
Scope
AST, ALT, GGPT
NCT03481894_exc_T42
Scope
Liver enzymes (either AST, ALT, GGPT), or direct bilirubin
NCT03481894_exc_T43
Value
Pathologically altered
NCT03481894_exc_T44
Measurement
level of any serum electrolyte
NCT03481894_exc_T45
Measurement
sodium
NCT03481894_exc_T46
Measurement
potassium
NCT03481894_exc_T47
Measurement
magnesium
NCT03481894_exc_T48
Measurement
calcium
NCT03481894_exc_T49
Measurement
chloride
NCT03481894_exc_T50
Measurement
phosphate
NCT03481894_exc_T51
Scope
sodium, potassium, magnesium, calcium, chloride, phosphate
NCT03481894_exc_T53
Value
Pathologically altered
NCT03481894_exc_T54
Measurement
blood pH
NCT03481894_exc_T55
Measurement
oxygen saturation
NCT03481894_exc_T56
Measurement
carbon dioxide
NCT03481894_exc_T57
Scope
blood pH, or oxygen saturation, or carbon dioxide
NCT03481894_exc_T58
Condition
lactation
NCT03481894_exc_T59
Condition
Pregnancy